4 days left! 

26-28 March, 2018
ProArte Maritim Hotel, Berlin, Germany


Multitude Therapeutics (MTX) is a preclinical-stage business unit created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy.MTX focuses on developing novel antibody-drug conjugates (ADC) and immuno-oncology (I/O) (T cells and macrophages) based antibody therapeutics for solid and blood tumors. MTX’s therapeutic programs are based on novel cancer and immune cell surface targets discovered by a massively parallel monoclonal antibody array (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by unprecedented antibody discovery capabilities built in Abmart –– the parent company in Shanghai.